ERBB2 and breast carcinoma: Trastuzumab deruxtecan-nxki (Enhertu®) against HER2, approved for solid cancers such as breast cancer in 2019, underwent endocytosis by binding to HER2-positive tumor cells and released the payload deruxtecan (DXd) by lysosomal cathepsins [29].